The promise and pitfalls of composite endpoints in sepsis and COVID-19 clinical trials.
Journal
Pharmaceutical statistics
ISSN: 1539-1612
Titre abrégé: Pharm Stat
Pays: England
ID NLM: 101201192
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
22
04
2020
revised:
18
08
2020
accepted:
25
08
2020
pubmed:
8
9
2020
medline:
16
3
2021
entrez:
7
9
2020
Statut:
ppublish
Résumé
Composite endpoints reveal the tendency for statistical convention to arise locally within subfields. Composites are familiar in cardiovascular trials, yet almost unknown in sepsis. However, the VITAMINS trial in patients with septic shock adopted a composite of mortality and vasopressor-free days, and an ordinal scale describing patient status rapidly became standard in COVID studies. Aware that recent use could incite interest in such endpoints, we are motivated to flag their potential value and pitfalls for sepsis research and COVID studies.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
413-417Informations de copyright
© 2020 The Authors. Pharmaceutical Statistics published by John Wiley & Sons Ltd.
Références
WHO R&D blueprint novel coronavirus (COVID-19) therapeutic trial synopsis. World Health Organization 2020 Web site. https://www.who.int/blueprint/priority-diseases/key-action/COVID-19_Treatment_Trial_Design_Master_Protocol_synopsis_Final_18022020.pdf Published February 18, 2020. Accessed August 11, 2020.
Matsouaka RA, Singhal AB, Betensky RA. Optimal weighted Wilcoxon-Mann-Whitney Test for prioritized outcomes. New Frontiers of Biostatistics and Bioinformatics. Switzerland: Springer; 2018:3-40.
Mebazaa A, Laterre PF, Russell JA, et al. Designing phase 3 sepsis trials: application of learned experiences from critical care trials in acute heart failure. J Intensive Care. 2016;4:24-24.
Finkelstein DM, Schoenfeld DA. Combining mortality and longitudinal measures in clinical trials. Stat Med. 1999;18:1341-1354.
Fujii T, Luethi N, Young PJ, et al. Effect of vitamin C, hydrocortisone, and thiamine vs hydrocortisone alone on time alive and free of vasopressor support among patients with septic shock: the VITAMINS randomized clinical trial. JAMA. 2020;323(5):423-431.
Novack V, Beitler JR, Yitshak-Sade M, et al. Alive and ventilator free: a hierarchical, composite outcome for clinical trials in the acute respiratory distress syndrome. Crit Care Med. 2020;48(2):158-166.
Harhay MO, Casey JD, Clement M, et al. Contemporary strategies to improve clinical trial design for critical care research: insights from the first critical care clinical Trialists workshop. Intensive Care Med. 2020;46(5):930-942.
Fowler AA 3rd, Truwit JD, Hite RD, et al. Effect of vitamin C infusion on organ failure and biomarkers of inflammation and vascular injury in patients with sepsis and severe acute respiratory failure: the CITRIS-ALI randomized clinical trial. JAMA. 2019;322(13):1261-1270.
Margulies KB, Anstrom KJ, Hernandez AF, et al. GLP-1 agonist therapy for advanced heart failure with reduced ejection fraction: design and rationale for the functional impact of GLP-1 for heart failure treatment study. Circ Heart Fail. 2014;7(4):673-679.
Felker GM, Maisel AS. A global rank end point for clinical trials in acute heart failure. Circ Heart Fail. 2010;3(5):643-646.
Cordoba G, Schwartz L, Woloshin S, Bae H, Gøtzsche PC. Definition, reporting, and interpretation of composite outcomes in clinical trials: systematic review. BMJ. 2010;341:c3920.
Brown PM, Ezekowitz JA. Examining the influence of component outcomes on the composite at the design stage. Circ Cardiovasc Qual Outcomes. 2018;11(6):e004419.
Pocock SJ, Clayton TC, Stone GW. Challenging issues in clinical trial design: part 4 of a 4-part series on statistics for clinical trials. J Am Coll Cardiol. 2015;66(25):2886-2898.
O'Brien PC, Dyck PJ, Tilley BC. Composite endpoints in clinical trials. Methods and Applications of Statistics in Clinical Trials. Chichester: Wiley; 2014:246-251.
Pocock SJ. Clinical trials with multiple outcomes: a statistical perspective on their design, analysis, and interpretation. Control Clin Trials. 1997;18(6):530-545.
Coste J, Fermanian J, Venot A. Methodological and statistical problems in the construction of composite measurement scales: a survey of six medical and epidemiological journals. Stat Med. 1995;14(4):331-345.
Guideline on clinical investigation of medicinal products for the treatment of acute heart failure. Committee for Medicinal Products for Human Use (CHMP). CPMP/EWP/2986/03 Rev. 1 Web site. https://www.ema.europa.eu/en/clinical-investigation-medicinal-products-treatment-acute-heart-failure. Accessed February 25, 2020.
Massie BM, O'Connor CM, Metra M, et al. Rolofylline, an adenosine A1−receptor antagonist, in acute heart failure. N Engl J Med. 2010;363(15):1419-1428.
Guideline on multiplicity issues in clinical trials. European Medicines Agency. Committee for Medicinal Products for Human Use (CHM). EMA/CHMP/44762/2017 Web site. https://www.ema.europa.eu/documents/scientific-guideline/draft-guideline-multiplicity-issues-clinical-trials_en.pdf. Published December 15, 2016. Accessed February 25, 2020.
Brown PM, Ezekowitz JA. Letter by Brown and Ezekowitz regarding article, "development and evolution of a hierarchical clinical composite end point for the evaluation of drugs and devices for acute and chronic heart failure: a 20-year perspective". Circulation. 2017;135(15):e889-e891.
Craig P, Dieppe P, Macintyre S, Michie S, Nazareth IMP. Developing and evaluating complex interventions: new guidance. Medical Research Council. https://www.mrc.ac.uk/documents/pdf/complex-interventions-guidance/. Published 2006. Accessed June 12, 2020.
Sjölander A, Vansteelandt S. Frequentist versus Bayesian approaches to multiple testing. Eur J Epidemiol. 2019;34(9):809-821.
Brown PM, Ezekowitz JA. Multitype events and the analysis of heart failure readmissions: illustration of a new modeling approach and comparison with familiar composite end points. Circ Cardiovasc Qual Outcomes. 2017;10(6):e003382.
Rogers JK, Jhund PS, Perez A-C, et al. Effect of Rosuvastatin on repeat heart failure hospitalizations: the CORONA trial (controlled Rosuvastatin multinational trial in heart failure). JACC: Heart Fail. 2014;2(3):289-297.
van Eijk RPA, Eijkemans MJC, Rizopoulos D, van den Berg LH. S N. comparing methods to combine functional loss and mortality in clinical trials for amyotrophic lateral sclerosis. Clin Epidemiol. 2018;10:333-341.
Mascha EJ, Sessler DI. Design and analysis of studies with binary- event composite endpoints: guidelines for anesthesia research. Anesth Analg. 2011;112(6):1461-1471.
Lee A, Chiu CH, Cho MWA, et al. Factors associated with failure of enhanced recovery protocol in patients undergoing major hepatobiliary and pancreatic surgery: a retrospective cohort study. BMJ Open. 2014;4(7):e005330.
Turan A, Grady M, You J, et al. Low vitamin D concentration is not associated with increased mortality and morbidity after cardiac surgery. PLoS One. 2013;8(5):e63831.
Senn S. Disappointing dichotomies. Pharm Stat. 2003;2(4):239-240.
Lewis JA. In defence of the dichotomy. Pharm Stat. 2004;3(2):77-79.
Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569-1578.
Herper M. Inside the NIH's controversial decision to stop its big remdesivir study. STAT Web site. https://www.statnews.com/2020/05/11/inside-the-nihs-controversial-decision-to-stop-its-big-remdesivir-study/. Published May 11, 2020. Accessed July 2, 2020.
Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of Remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA. 2020. https://doi.org/10.1001/jama.2020.16349.
McCreary EK, Angus DC. Efficacy of Remdesivir in COVID-19. JAMA. 2020. https://doi.org/10.1001/jama.2020.16337.
Desai A, Gyawali B. Endpoints used in phase III randomized controlled trials of treatment options for COVID-19. EClinicalMedicine. 2020;23:100403.
Brown PM, Anstrom KJ, Felker GM, Ezekowitz JA. Composite end points in acute heart failure research: data simulations illustrate the limitations. Can J Cardiol. 2016;32(11):1356.e1321-1356.e1328.
Sun H, Davison Beth A, Cotter G, Pencina Michael J, Koch GG. Evaluating treatment efficacy by multiple end points in phase II acute heart failure clinical trials. Circ Heart Fail. 2012;5(6):742-749.
ICH E9 (R1) addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials. EMA/CHMP/ICH/436221/2017 Web site. https://www.ema.europa.eu/documents/scientific-guideline/ich-e9-r1-addendum-estimands-sensitivity-analysis-clinical-trials-guideline-statistical-principles_en.pdf. Published February 17, 2020. Accessed February 12, 2020.
Wong JLC, Mason AJ, Gordon AC, Brett SJ. Are large randomised controlled trials in severe sepsis and septic shock statistically disadvantaged by repeated inadvertent underestimates of required sample size? BMJ Open. 2018;8(8):e020068.